Kriolen

Ambroxol Hydrochloride, the active ingredient in Kriolen, is a mucolytic presented as an oral formulation for oral use. It is used to facilitate the clearance of thick mucus in respiratory conditions such as acute and chronic bronchitis, COPD, and upper respiratory tract infections.

GNH USA supplies Kriolen as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to GMP standards and provides regulatory‑compliant packaging for global distribution. It ensures product integrity through stringent quality control and traceability throughout the supply chain.

Ambroxol Hydrochloride is a mucolytic that acts on respiratory mucus production and clearance.

- Acute and chronic bronchitis: helps loosen and clear thick bronchial secretions, improving cough efficiency. - Cough with thick or viscous sputum: reduces sputum viscosity, facilitating expectoration. - Chronic obstructive pulmonary disease (COPD): aids mucus clearance, supporting airway patency. - Upper respiratory tract infections: assists in clearing mucus, relieving congestion and cough.

Common Side Effects: - Altered taste sensation: a transient bitter or salty taste. - Nausea: mild gastrointestinal discomfort. - Abdominal discomfort: occasional stomach cramps. - Diarrhea: loose stools in some patients. - Headache: mild to moderate intensity. - Skin rash: mild erythema or itching.

Serious or Rare Side Effects: - Anaphylactic reaction: severe allergic response requiring immediate medical attention. - Stevens‑Johnson syndrome: rare severe skin eruption. - Hepatic enzyme elevation: potential liver function alteration. - Eosinophilia or neutropenia: abnormal blood cell counts. - Severe bronchospasm: paradoxical airway constriction.

Before initiating therapy, consider the following precautions: - Assess renal function: adjust use in patients with severe renal impairment. - Monitor for hypersensitivity: discontinue if allergic reactions occur. - Caution in asthma: may provoke bronchospasm in susceptible individuals. - Avoid in known hypersensitivity to ambroxol or related compounds. - Use during pregnancy and lactation only if clearly needed after risk‑benefit assessment. - Store at ambient temperature: keep in the original pack, protect from moisture and heat.

Ambroxol Hydrochloride may interact with other medicines as follows:

Major Interactions (Avoid): - Concurrent use with codeine‑containing antitussives: may diminish mucolytic effectiveness. - Combination with other mucolytics (e.g., N‑acetylcysteine): risk of excessive mucus thinning.

Moderate Interactions (Monitor Closely): - Bronchodilators (e.g., salbutamol): monitor for additive respiratory effects. - Anticoagulants (e.g., warfarin): observe for any change in bleeding tendency. - CYP450 inhibitors: theoretical increase in ambroxol plasma levels; monitor clinical response.